negative symptom

negative symptom

one of the deficit symptoms of schizophrenia that follow from diminished volition and executive function including inertia, anergia, lack of involvement with the environment, poverty of thought, social withdrawal, and blunted affect.

negative symptom

diminishing or absence of a characteristic of normal health as an indication of disease, such as the flat affect or mutism sometimes seen in schizophrenia. Compare positive symptom.

negative symptom

Any symptom involving loss of normal mental function, as seen in schizophrenia, psychosis, depression and other mental disorders.
 
Examples
Blunting or decreased range of affect; loss of will, pleasure, sense of purpose and social drives; inhibited fluency and content of speech, and range of motion; poverty of speech, movement and motivation; loss of interests in previously enjoyable activities.

negative symptom

Deficit symptom Psychiatry Any Sx involving loss of normal mental function, seen in schizophrenia, depression, and other mental disorders Examples Blunting of or ↓ range of affect, loss of will, pleasure, fluency, and content of speech, range of emotion, sense of purpose, social drives, poverty of speech, loss of interests. See Positive and Negative Symptom Scale, Schizophrenia. Cf Positive symptom.

neg·a·tive symp·tom

(neg'ă-tiv simp'tŏm)
One of the deficit symptoms of schizophrenia that follow from diminished volition and executive function including inertia, anergia, lack of involvement with the environment, poverty of thought, social withdrawal, and blunted affect.
References in periodicals archive ?
The symptoms affected patients' lives, and the patients used either positive or negative symptom management strategies, leading to either positive or negative results during symptom management.
Further, based on accumulating evidence [20-21] that negative symptoms are not unidimensional and are best represented by two facets--expression, which captures emotion, expression, and speech; and motivation and pleasure, which captures motivation and pleasure for engaging in social, vocational, and recreational activities--we divided the negative symptom items from Wallwork et al.
This becomes more disheartening against the backdrop that people with a DUP <1 year show substantially greater negative symptom reduction, especially when DUP is <9 months, compared with those with a DUP of >1 year.
But a significant decrease was seen in the negative symptom of alogia factor score (12).
Post hoc comparisons using the Bonferroni procedure indicated that individuals in Cluster 2, the most severe group with the poorest attention and memory function in our study, had the highest mean negative symptom score of 18.
Although as an acute schizophrenia trial, ITI-007-005 was not designed to look just at negative symptoms of schizophrenia, the investigators predefined a subgroup population analysis of patients who had prominent negative symptoms at baseline (defined as a score of 4 or more on at least three negative symptom items on the PANSS at baseline).
The severity of patients' psychotic symptoms were reflected by positive symptom factor scores, negative symptom factor scores, general psychopathological scale factor scores and the total scores of PANSS.
At the end of the double-blind treatment period, analysis of exploratory endpoints showed a greater mean worsening of symptoms in placebo- vs cariprazine-treated patients on all efficacy parameters as measured by Positive and Negative Syndrome Scale (PANSS) total and subscale scores, the Clinical Global Impressions-Severity (CGI-S) rating scale, the 16-Item Negative Symptom Assessment (NSA-16) and the Personal and Social Performance Scale (PSP) total score, concluded the company.
Only schizophrenia patients with a score below 6 on the Positive and Negative Symptom Scale (PANSS) were included.
24) The domains of social functioning were found to be significantly negatively correlated with the PANSS negative symptom scale, positive symptom scale, and overall symptoms.
Cariprazine at 3-6 mg/day outperformed placebo in all but the Marder negative symptom factor grouping, where a trend favoring the drug fell short of statistical significance.
CTP-692 is being developed as a potential adjunctive therapy to antipsychotic medicines with the potential to improve positive and negative symptoms as well as cognitive function in these patients.